Omeprazole
Proton Pump Inhibitors
Sold as Acid Reducer · LOSEC · LOSEC MUPS · HEARTBURN CONTROL
- Drug class
- Proton Pump Inhibitors
- Availability
- Prescription and OTC
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 170
- FDA reports (12 mo)
- 16,884
Overview
Plain-language summary, compiled from the cited regulatory records
Omeprazole is a medication belonging to the drug class of Proton Pump Inhibitors [1]. It is approved for the treatment of frequent heartburn, which is defined as heartburn occurring 2 or more days per week [1]. This medication is not intended for immediate relief of heartburn symptoms and may require 1 to 4 days to achieve its full effect [1].
Omeprazole is available under various brand names, including Acid Reducer [1]. In the past 12 months, there have been 16,884 adverse event reports associated with this active ingredient [2]. The most frequently reported adverse events include diarrhea, fatigue, nausea, off-label use, and headache [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 117 | May 29, 2026 |
| US United States | FDA | 35 | April 17, 2026 |
| CA Canada | Health Canada | 18 | May 13, 2026 |
GBUnited Kingdom· MHRA
117 products
Uses
Omeprazole Oral Suspension is indicated for:
Paediatric use Children 1-12 months of age • Treatment of reflux esophagitis • Symptomatic treatment of heartburn and acid regurgitation in gastro-esophageal reflux disease
How to take
USUnited States· FDA
35 products
Uses
Use(s) treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect
How to take
CACanada· Health Canada
18 products
Uses
, heartburn and regurgitation; • Zollinger-Ellison syndrome (pathological hypersecretory condition); • eradication of Helicobacter pylori (H. pylori). LOSEC, in combination with clarithromycin and either amoxicillin or metronidazole, is indicated for the treatment of patients with peptic ulcer disease associated with Helicobacter pylori infection.
, asymptomatic) remains to be determined. 1 Pediatrics No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness.
How to take
Drug interactions
Known interactions involving Omeprazole. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL341110005 · revised May 22, 2026
- [2]FDA DailyMed · 0057cb91-fc5e-8e… · revised November 10, 2024 [PDF]
- [3]Health Canada (DPD) · 00846503 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.